Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07518979) titled 'EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer' on April 1.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Jiyan Liu

Condition: Penile Cancer

Intervention: Drug: Becotatug Vedotin

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: May 1, 2026

Target Sample Size: 60

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07518979

Published by...